Trial Profile

A clinical phase IIa study of Sevuparin in patients with anemia of chronic kidney disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Apr 2025 According to Modus Therapeutics media release, further study updates are expected in the first half of 2025.
02 Apr 2025 According to Modus Therapeutics media release , the company announced the opening of second site located at the Unita di Nefrologia e Dialisi, Istituti Clinici Scientifici Maugeri S.p.A., in Pavia, Italy.
31 Mar 2025 According to Modus Therapeutics media release, the company has procured a bridge financing of up to SEK 5.0 million from its largest shareholder, Karolinska Development, which will support Modus to maintain the momentum of this ongoing Phase IIa study for anemia in CKD, including the completion of Part 1 of this study, and preparations for Part 2.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com